$19.66
-0.01-0.05%
Last update: Oct 22, 6:36 PM
Silence Therapeutics PLC (SLN) Stock Price, Quote, News & History
SLNNASDAQ
Silence Therapeutics (SLN) leaps 126% on a $1.3B cash acquisition by Merck KGaA at $20 per ADS. Deal expected to close Q1 2027.
You can purchase shares of Silence Therapeutics (NASDAQ:SLN) through any online brokerage.
Other companies in Silence Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Silence Therapeutics has a consensus price target of $31.67.
The stock price for Silence Therapeutics (NASDAQ: SLN) is $19.6034 last updated October 22, 2026 at 6:36 PM EDT.
There are no upcoming dividends for Silence Therapeutics.
Silence Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Silence Therapeutics.
Silence Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates...
